无定形固体分散体开发中喷雾干燥与热熔挤出的详细比较

Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.

Introduction

Amorphous solid dispersions (ASDs) have become one of the most widely adopted enabling oral formulation strategies for poorly soluble drug candidates. By converting crystalline APIs into high-energy amorphous systems, ASDs significantly improve dissolution and oral bioavailability.[1]

Among ASD manufacturing technologies, two platforms dominate pharmaceutical development:

• Spray Drying (SD)
• Hot Melt Extrusion (HME)

Both technologies can successfully generate amorphous solid dispersions, yet they differ fundamentally in:

• Process design
• API compatibility
• Scalability
• Physical stability
• Manufacturing complexity
• Regulatory strategy

Choosing the wrong platform can create:

• Stability failures
• Scale-up bottlenecks
• Excessive material consumption
• Delayed IND timelines
• Reformulation risks

This guide provides a structured comparison between spray drying and hot melt extrusion to help development teams identify the optimal ASD manufacturing strategy for their molecule.

Why ASD Manufacturing Strategy Matters

The success of an ASD program depends not only on formulation composition, but also on how the amorphous system is manufactured.

A successful ASD platform must balance:

• Supersaturation performance
• Physical stability
• Process robustness
• Scalability
• Regulatory readiness
• Cost efficiency

The manufacturing platform directly influences:

• Particle morphology
• Residual solvent profile (for SD)
• Drug-polymer miscibility
• Molecular mobility
• Long-term stability

Key takeaway: Spray drying and HME should be viewed as complementary technologies rather than interchangeable processes.

How Spray Drying Works

Mechanism

Spray drying creates ASDs by dissolving the API,polymer, and other excipients (if any) in an organic solvent system, followed by rapid solvent evaporation.

Process steps

1. Dissolution of API,polymer, and other excipients (if any)
2. Atomization into micron-sized droplets
3. Rapid solvent evaporation
4. Formation of amorphous solid particles
5. Secondary drying

The extremely fast drying kinetics can "freeze" the drug in a high-energy amorphous state before recrystallization occurs.[2]

Key Advantages

Excellent for heat-sensitive APIsBecause exposure to elevated temperature is brief, spray drying is often preferred for:

• Thermally labile compounds
• Peptides
• Complex molecules

Broad polymer compatibility

Supports a wide range of ASD polymers: HPMC-AS, PVP/VA, Soluplus, HPMC, Eudragit® etc.

Superior particle engineeringEnables good control over particle size, density, surface area, and morphology – improving dissolution, downstream manufacturability, and aerosolization performance.

Challenges

• Solvent requirements – API and all the excipients must dissolve in a common solvent system; poor compatibility may limit feasibility.
• Residual solvent management – Requires monitoring, drying optimization, and regulatory control.
• Scale-up complexity – Needs solvent handling infrastructure, explosion protection, EHS on emission, and advanced process control.

How Hot Melt Extrusion (HME) Works

Mechanism

Hot melt extrusion forms ASDs by processing drug-polymer and plasticizer/surfactant (if any) blends under elevated temperature and mechanical shear.

Process steps

1. Feeding by separate feeders/liquid injectors, or pre-blending
2. Heating within the extruder barrel
3. Shear-induced mixing and amorphization
4. Continuous extrusion and solidification

Unlike spray drying, HME is a solvent-free process.[3]

Key Advantages

Solvent-free manufacturingEliminates organic solvents, residual solvent concerns, and solvent recovery – simplifying EHS management, regulatory considerations, and manufacturing operations.

Continuous manufacturing capabilityHighly compatible with continuous strategies – offering process consistency, high throughput, reduced batch variability, and scalable production.

Challenges

• Thermal stress – API must be melt and tolerate elevated temperature and mechanical shear; Not suitable for thermally sensitive compounds with high melting point or Tg..
• Polymer limitations – Not all ASD polymers process well under extrusion conditions; viscosity and melt behavior strongly affect manufacturability.
• Limited particle engineering – Typically produces dense extrudates requiring milling and downstream processing, reducing flexibility in particle design.

Head-to-Head Comparison

When to Choose Spray Drying

Spray drying is generally preferred when:

✓ The API is heat sensitive – Compounds susceptible to thermal degradation are often better suited for spray drying.

✓ Solvent solubility is favorable – API and polymer dissolve in compatible solvent systems.

✓ Advanced particle engineering is required – Advantageous for inhalation products, controlled particle morphology, and rapid dissolution enhancement.

✓ Early feasibility speed matters – Small-scale spray drying enables rapid ASD screening with limited API quantities.

When to Choose HME

HME is often preferred when:

✓ The API is thermally stable – Compounds stable at elevated temperatures are strong candidates for extrusion.

✓ Solvent-free manufacturing is desired – HME avoids solvent handling, drying operations, and residual solvent concerns.

✓ Continuous manufacturing is a priority – Aligns well with process intensification, commercial scalability, and continuous processing strategies.

Can Spray Drying and HME Be Evaluated in Parallel?

Yes — and increasingly, they should be.

Many development teams now perform comparative ASD feasibility studies using spray drying, HME, and multiple polymers in parallel during early development.

This approach enables:

• Faster platform selection
• Lower reformulation risk
• More informed scale-up planning

Material-sparing workflows can often evaluate both approaches using 30-50g of API

Key Development Considerations

Spray Drying Challenges

• Solvent selection complexity
• Residual solvent management
• Long processing time due to low solid% in the spray solution

HME Challenges

• Thermal degradation
• Polymer melt viscosity
• Milling and downstream processing requirements

Crystal Pharmatech's ASD Development Strategy

Crystal Pharmatech provides integrated ASD development capabilities spanning:

• Early feasibility
• Composition screening
• Process optimization
• Analytical characterization
• GMP clinical manufacturing

Spray Drying Capabilities

• Lab-scale to GMP spray drying
• Solvent system optimization
• Particle engineering
• Dissolution enhancement studies

HME Capabilities

• Rheological characterization
• Twin-screw extrusion
• Processing optimization
• Thermal compatibility evaluation
• Extrudate downstream processing

Advanced Analytical Support

• XRPD, DSC, TGA, Rheometer, Compaction simulation, ssNMR, MicroED
• Dissolution and supersaturation analysis

First-Time-Right Development Philosophy

Crystal Pharmatech applies a science-driven "First-Time-Right" workflow integrating:

• Physicochemical profiling
• Solid-state characterization
• PBPK modeling
• Comparative feasibility assessment

This approach minimizes development risk while accelerating progression toward IND-enabling studies.

Summary: Spray Drying vs HME

Neither platform is universally superior.

The optimal ASD manufacturing strategy depends on:

• API thermal behavior
• Solvent compatibility
• Physical stability requirements
• Scale-up strategy
• Commercial manufacturing goals

For many compounds, early comparative feasibility studies provide the fastest and lowest-risk path to selecting the right technology.

Frequently Asked Questions

Is spray drying or HME better for my compound?

Spray drying is generally preferred for heat-sensitive or solvent-soluble compounds, while HME is advantageous for thermally stable compounds and solvent-free continuous manufacturing.

Which ASD platform has better scalability?

Both platforms scale successfully, but HME is particularly well suited for continuous commercial manufacturing.

Does spray drying always require organic solvents?

Yes, most spray drying processes use organic solvents or mixed solvent systems, although water can be added for solubilizing certain surfactants.

Is HME more stable than spray drying?

No. Stability ultimately depends on formulation composition, processing, and storage conditions.

Can both technologies be screened during feasibility?

Yes. Many development programs evaluate spray drying and HME in parallel using material-sparing workflows. However, significantly larger amounts of API is needed for HME.

References

1. Jermain SV, et al. Molecular Pharmaceutics, 2018.
2. Bhujbal SV, et al. International Journal of Pharmaceutics, 2021.
3. Hancock BC, Zografi G. Journal of Pharmaceutical Sciences, 1997.
4. Williams RO, et al. Formulating Poorly Water Soluble Drugs, Springer, 2016.

Read the original article and source figures